Sable Bio secures £1.5m in pre seed funding led by Episode 1 Ventures to scale its drug safety platform.
The pre seed round was led by Episode 1 Ventures and will support infrastructure development and team expansion.
Sable Bio develops an artificial intelligence platform designed to help pharmaceutical companies identify safety risks early in the drug discovery process. The London-based startup provides predictive insights to reduce the risk of clinical trial failures.
Sable Bio has secured £1.5m in a pre seed funding round led by Episode 1 Ventures, with participation from Seedcamp and Siddhant Jayakumar. The capital will be directed towards expanding the team of scientists and engineers and strengthening the core technological infrastructure.
Established by former BenevolentAI researchers, the London based company builds tools to help scientists identify and mitigate safety risks during drug discovery. The fresh injection of capital aims to support the firm as it refines its data capabilities and establishes academic and commercial partnerships across the life sciences sector.
From the founder
"We are really excited, this investment will help Sable Bio redefine drug safety assessment and change the ways actionable biomedical insights are generated. Working with with leading investors Episode 1 and Seedcamp is enabling us to build an exceptional team and a platform to accelerate safer drug development for patients in need"
Josh Almond-Thynne
co-founder and CEO at Sable Bio
Use of funds
- 01Grow the team
- 02Build out infrastructure
